Lepu Biopharma Announces Promising Results for MRG003 in Pivotal Clinical Trial for Nasopharyngeal Cancer at 2025 ASCO Annual Meeting

Reuters
Jun 01
Lepu Biopharma Announces Promising Results for MRG003 in Pivotal Clinical Trial for Nasopharyngeal Cancer at 2025 ASCO Annual Meeting

Lepu Biopharma Co. Ltd. has announced the results of a pivotal clinical trial for their drug candidate, MRG003, which were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study focused on the treatment of recurrent or metastatic nasopharyngeal cancer (R/M NPC) using MRG003, a novel EGFR-targeted antibody-drug conjugate. In a randomized-controlled, multicenter, open-label study, MRG003 demonstrated statistically and clinically significant benefits in heavily pretreated patients compared to chemotherapy. The trial enrolled 173 patients, with MRG003 showing a higher objective response rate of 30.2% compared to 11.5% for chemotherapy. The study highlights a potential shift in treatment paradigms for R/M NPC. However, the company cautions that there is no guarantee of MRG003's successful development and market launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lepu Biopharma Co. Ltd. published the original content used to generate this news brief on June 01, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10